Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Environmental Surface Solutions

- PMLiVE

UK to provide genomic sequencing globally to identify COVID-19 variants

Public Health England has identified the first group of countries to receive genomic sequencing support through NVAP

- PMLiVE

WHO recommends ‘life-saving’ IL-6 inhibitors for severe COVID-19

Roche's Actemra and Sanofi's Kevzara are included in WHO's updated patient care guidelines

- PMLiVE

Israel study suggests Pfizer/BioNTech vaccine is less effective against Delta variant

Data suggests vaccine is 64% effective at preventing infection caused by Delta variant after two doses

- PMLiVE

Bharat Biotech says its COVID-19 vaccine is 77.8% effective overall

US development partner Ocugen is already planning to submit a BLA for the vaccine to the FDA

- PMLiVE

J&J’s COVID-19 vaccine shows ‘strong’ activity against Delta variant

Vaccine produces durable immune responses lasting up to eight months

- PMLiVE

COVID-19 booster dose programme planned for September launch in Britain

The programme will be conducted in two stages for a range of priority groups

Open-Data Platforms for Direct Engagement with Patients, Researchers, and Pharma

Indu Navar, CEO and Founder of EverythingALS, explores the roles of Artificial Intelligence, Machine Learning, and Brain Computer Interface in the search for a cure for ALS. She will also...

Impetus Digital

Moving Away from Hospital-Centered Care: Barriers & Opportunities

David Barthel, CEO of Health Logic Interactive Inc., discusses their lab-on-chip, point-of-care platform technology for CKD. He also explores the issues with the hospital-centered model of care, shares his tips...

Impetus Digital

- PMLiVE

Cambridge University scientists identify 160 new drugs with COVID-19 repurposing potential

Scientists highlighted the potential of two drugs, one for rheumatoid arthritis and one for malaria

- PMLiVE

WHITE PAPER: From bench to bedside in one year – how the race for a COVID-19 vaccine will change the future of drug development

In this edition of MAGNIFI, we discuss the factors behind this acceleration in development of the COVID-19 vaccines and what this might mean for the future of pharma

IGNIFI

- PMLiVE

Final data shows CureVac’s COVID-19 vaccine is only 48% effective

New data shows slight improvement over previously reported 47% overall efficacy in interim analysis

Report

Digital Health Tools - Physician Trends

Research Partnership

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links